Immunotech Laboratories, Inc. Provides Funding Update

Immunotech in Discussions With New Financing Group

        Print
| Source: Immunotech Laboratories

MONROVIA, Calif., April 29, 2013 (GLOBE NEWSWIRE) -- Immunotech Laboratories, Inc. (Pink Sheets:IMMB) today announced that they are in preliminary discussions with a large potential funding group out of Dubai. The group has shown interest in the future development and support of the Company's future FDA clinical trials.

Blaine Nabors, Vice President of Business Development for Immunotech, stated, "We have had several separate discussions, and an agreement-in-principal will hopefully be reached by the middle of next week. Immunotech's strategic relationships such as this potential one are critical as we strive to further advance our Inactivated Pepsin Fraction (IPF) technology."

About Immunotech Laboratories                                                                           

Immunotech Laboratories, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Visit www.immunotechlab.com.

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its press releases and periodic reports filed with the SEC. IPF is not approved by the U.S. Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech believes that the forward-looking statements and underlying assumptions contained herein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, no person should consider the forward-looking statements herein as a representation.

Actual results could differ materially from current projections or implied results. Immunotech Laboratories, Inc. undertakes no obligation to revise these statements following the date of this news release.

Company Contact


Blaine Nabors: 713-875-9200
E-mail: